The Use and Misuse of Psychiatric Drugs: An Evidence-Based Critique

The Use and Misuse of Psychiatric Drugs: An Evidence-Based Critique

Volumn , Issue , 2010, Pages

  Paris, Joel ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84891585389     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470666630     Document Type: Book

References (424)

1. Abrams, R. and Taylor, M.A. (1981) Importance of schizophrenic symptoms in the diagnosis of mania. American Journal of Psychiatry, 138, 658-661.
2. Achenbach, T.M. and McConaughy, S.H. (1997) Empirically Based Assessment of Child and Adolescent Psychopathology, practical applications, 2nd edn, Sage Publications, Thousand Oaks, CA.
3. Ackner, B., Harris, A., and Oldham, A.J. (1957) Insulin treatment in schizophrenia: a controlled trial. Lancet, 265, 607-611.
4. Akiskal, H.S. (2002) The bipolar spectrum: the shaping of a new paradigm in psychiatry. Current Psychiatry Reports, 4, 1-3.
5. Akiskal, H.S. (2004) Demystifying borderline personality: critique of the concept and unorthodox reflections on its natural kinship with the bipolar spectrum. Acta Psychiat Scand, 110, 401-407.
6. Akiskal, H.S. and Benazzi, F. (2003) Family history validation of the bipolar nature of depressive mixed states. Journal of Affective Disorders, 73, 113-118.
7. Akiskal, H.S. and McKinney, W.T. Jr. (1973) Depressive disorders: toward a unified hypothesis. Science, 182, 20-29.
8. Akiskal, H.S., Akiskal, K.K., Lancrenon, S. et al. (2006) Validating the bipolar spectrum in the French National EPIDEP Study: overview of the phenomenology and relative prevalence of its clinical prototypes. Journal of Affective Disorders, 96, 197-205.
9. Alda, M. (1999) Pharmacogenetics of lithium response in bipolar disorder. Journal of Psychiatry and Neuroscience, 24, 154-158.
10. Alda, M. (2009) Is monotherapy as good as polypharmacy in long-term treatment of bipolar disorder? Canadian Journal of Psychiatry, 54, 719-725.
11. Alphs, R., Anand, R., Islam, M.Z. et al. (2004) The International Suicide Prevention Trial (InterSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients. Schizophrenia Bulletin, 30, 577-586.
12. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, 4th edn (text revision), Author, Washington, DC. The Use and Misuse of Psychiatric Drugs: An Evidence-Based Critique Joel Paris
13. American Psychiatric Association (2002) Practice Guideline for the Treatment of Patients with Major Depressive Disorder, 2nd edn, American Psychiatric Press, Washington, DC.
14. American Psychiatric Association (2004) Practice Guideline for the Treatment of PatientsWith Schizophrenia, 2nd edn, American Psychiatric Press, Washington, DC.
15. Anderson, I.M. (1998) SSRIs versus tricyclic antidepressants in depressed inpatients: A meta-analysis of efficacy and tolerability. Depression and Anxiety, 7(1), 11-17.
16. Andreasen, N.C. (2001) Brave New Brain: Conquering Mental Illness in the Era of the Genome, Oxford University Press, New York.
17. Andreescu, C., Mulsant, B.H., Peasley-Miklus, C. et al. (2007) Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features STOP-PD Study Group. Journal of Clinical Psychiatry, 68, 194-200.
18. Angell, M. (2000) Is academic medicine for sale? NEJM, 342, 1516-1518.
19. Angell, M. (2005) The Truth about the Drug Companies: How They Deceive Us and What to Do about It, Random House, New York.
20. Angst, J., and Gamma, A. (2002) A new bipolar spectrum concept: a brief review. Bipolar Disorders, 4, 11-14.
21. Avorn, J. (2004) Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs, Knopf, New York.
22. Baastrup, P.C. and Schou, M. (1967) Lithium as a prophylactic agent. Its effect against recurrent depressions and manic-depressive psychosis. Archives of General Psychiatry, 16, 162-172.
23. Baldessarini, R.J., Ghaemi, S.N., and Viguera, A.C. (2002) Tolerance in antidepressant treatment. Psychotherapy and Psychosomatics, 71, 177-179.
24. Baldessarini, R.J., Tondo, L.,Davis, P. et al. (2006) Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disorders, 8, 625-639.
25. Balfour, R. and Richards, J. (2007) History of the British Confederation of Psychotherapists. British Journal of Psychotherapy, 11, 422-426.
26. Barkley, R. (2006) Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment, 3rd edn, Guilford, New York.
27. Barratt, A.,Wyer, P.C., Hatala, R. et al. (2004) Tips for learners of evidencebased medicine: 1. Relative risk reduction, absolute risk reduction and number needed to treat. Canadian Medical. Association Journal, 171, 353-358.
28. Bauer, M., and Dopfmer, S. (1999) Lithium augmentation in treatmentresistant depression: meta-analysis of placebo controlled studies. Journal of Clinical Psychopharmacology, 19, 427-434.
29. Bauer, M., Pretorius, H.W., Constant, E.L. et al. (2009) Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. Journal of Clinical Psychiatry, 70, 540-549.
30. Beck, A.T. (1986) Cognitive Therapy and the Emotional Disorders, Basic, New York.
31. Beck, A.T. (2008) The evolution of the cognitive model of depression and its neurobiological correlates. American Journal of Psychiatry, 165, 969-977.
32. Beck, S., and Olek, A. (2003) The Epigenome: Molecular Hide and Seek, John Wiley & Sons, Ltd, London.
33. Benedetti, F. (2008) Placebo Effects: Understanding the Mechanisms in Health and Disease, Oxford University Press, New York.
34. Bentall, R.P. (2003) Madness Explained. Psychosis and Human Nature, Penguin, London.
35. Benazzi, F. (2004) Factor structure of recalled DSM-IV hypomanic symptoms of bipolar II disorder. Comprehensive Psychiatry, 45, 441-446.
36. Berman, R.M., Marcus, R.N., and Swanink, R. (2007) The efficacy and safety of aripiprazole as adjunctive therapy inmajor depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry, 68, 843-853.
37. Bhatia, S.K., Rezac, A.J.,Vitiello, B. et al. (2008) Antidepressant prescribing practices for the treatment of children and adolescents. Journal of Child and Adolescent Psychopharmacology, 18, 70-80.
38. Binks, C.A., Fenton, M., McCarthy, L. et al. (2006) Pharmacological interventions for people with borderline personality disorder. Cochrane Database of Systematic Reviews 1 (Art. No.: CD005653). DOI: 10.1002/14651858.CD005653
39. Birmaher, B., Axelson, D., Goldstein, B., and Strober, M. (2009) Four-year longitudinal course of children and adolescents with bipolar spectrum disorders: The Course and Outcome of Bipolar Youth (COBY) Study. American Journal of Psychiatry, 166, 795-804.
40. Blier, P. (2008) Do antidepressants really work?. Journal of Psychiatry & Neuroscience, 33, 89-90.
41. Blier, P.,Ward, H.E.,Tremblay, P. et al. (2010) Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. American Journal of Psychiatry, 167, 281-288.
42. Bond, A. (2005) Antidepressant treatments and human aggression. European Journal of Pharmacology, 526, 218-225.
43. Bowden, C.L. (2007) Spectrum of effectiveness of valproate in neuropsychiatry. Expert Review of Neurotherapeutics, 7, 9-16.
44. Bowden, C.L., Brugger, A.M., Swann, A.C. et al. (1994) Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA, 271, 918.
45. Bowden, C.L., Calabrese, J.R., McElroy, S.L. et al. (2000) A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with Bipolar I disorder. Archives of General Psychiatry, 57, 481-489.
46. Bowden, C.J., Calabrese, J.R., Sachs, G., Yatham, L.N., Asghar, S.A., Hompland, M., Montgomery, P., Earl, N., Smoot, T.M., DeVeaugh-Geiss, J. for the Lamictal 606 Study Group (2003) A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry, 60, 392-400.
47. Braff, D.L., Freedman, R., Schork, N.J., and Gottesman I.I. (2007) Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder. Schizophrenia Bulletin, 33, 21-32.
48. Brezo, J., Paris, J., Tremblay, R., Vitaro, F., Hébert, M., Turecki, G. (2007) Distal and proximal correlates of suicide attempts in suicidal ideators: A population-based study. Psychol Med., 37, 1563-1574.
49. Brooke, N.S., Wiersgalla, M., and Salzman, C. (2005) Atypical uses of atypical antipsychotics. Harvard Review of Psychiatry, 13, 317-339.
50. Brotman, M.A., Schmajuk, M., Rich, B.A. et al. (2006) Prevalence, clinical correlates, and longitudinal course of severe mood dysregulation in children. Biological Psychiatry, 60, 991-997.
51. Brunette, M.F., Noordsy, D.L., Xie, H., and Drake, R.E. (2003) Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders. Psychiatric Services, 54, 1395-1401.
52. Butler, A.C., Chapman, J.E., Forman, E.M., and Beck, A.T. (2006) The empirical status of cognitive-behavioral therapy: A review of meta-analyses. Clinical Psychology Review, 26, 17-31.
53. Cade, J.F.J. (1949) Lithium salts in the treatment of psychotic excitement. Medical Journal of Australia, 36, 349-352.
54. Calton, T., Ferriter, M., Huband, N., and Spandler, H. (2008) A systematic review of the Soteria paradigm for the treatment of people diagnosed with schizophrenia. Schizophrenia Bulletin, 34, 181-192.
55. Campbell, E.G., Gruen, R.L., Mountford, J. et al. (2007) A national survey of physician-industry relationships. NEJM, 356, 1742-1750.
56. Carlson, C.L., and Mann, M. (2000) Attention-deficit/hyperactivity disorder, predominantly inattentive subtype. Child and Adolescent Psychiatric Clinics of North America, 9, 499-510.
57. Caroff, S.N., and Mann, S.C. (1993) Neuroleptic malignant syndrome. Med Clin North Am, 77, 185-202.
58. Carroll, B.J. (2009) Aripiprazole in refractory depression? Journal of Clinical Psychopharmacology, 29, 90-91.
59. Carroll, B.J., and Rubin, R.T. (2003) Editorial policies on financial disclosure. Nature Neuroscience, 6, 999-1000.
60. Casacalenda, N., and Boulenger, J.P. (1998) Pharmacologic treatments effective in both generalized anxiety disorder and major depressive disorder: clinical and theoretical implications. Canadian Journal of Psychiatry, 43, 722-730.
61. Caspi, A., Moffitt, T.E., Newman, D.L., and Silva, P.A. (1996) Behavioral observations at age three predict adult psychiatric disorders: longitudinal evidence from a birth cohort. Archives of General Psychiatry, 53, 1033-1039.
62. Caspi, A., McClay, J., Moffitt, T.E. et al. (2002) Role of genotype in the cycle of violence in maltreated children. Science, 297, 851-854.
63. Caspi, A., Sugden, K., Moffitt, T.E. et al. (2003) Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science, 301, 386-389.
64. Cipriani, A., Barbul, C., and Geddes, J. (2005) Suicide, depression, and antidepressants. BMJ, 330, 373-374.
65. Cipriani, A., Pretty, H., Hawton, K., and Geddes, J.R. (2005) Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. American Journal of Psychiatry, 162, 1805-1819.
66. Cipriani, A.A., Furukawa, T.A., Salanti, G. et al. (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multipletreatments meta-analysis. Lancet, 373, 746-758.
67. Cipriani, A., Rendell, J.M., and Geddes, J. (2009) Olanzapine in long-term treatment for bipolar disorder. Cochrane Database of Systematic Reviews 21 (1) (Art. No.: CD004367). DOI: 10.1002/14651858.CD004367.pub2
68. Cochrane, A.L. (1972) Effectiveness and Efficiency. Random Reflections on Health Services, Nuffield Provincial Hospitals Trust, London.
69. Collins, A. (1988) In the Sleep Room, Lester and Orpen Dennys, Toronto.
70. Conrad, P. (2007) The Medicalization of Society, John Hopkins University Press, Baltimore.
71. Cooper, J.E., Kendell, R.E., and Gurland, B.J. (1972) Psychiatric Diagnosis in New York and London, Oxford University Press, London.
72. Correll, C.U., Leucht, S., and Kane, J.M. (2004) Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of one-year study. Am J Psychiatry 161, 414-425.
73. Correll, C.U., and Leucht, S. (2007) Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. Journal of the American Academy of Child & Adolescent Psychiatry, 46, 687-700.
74. Corrigan, P.W. (ed.) (2005) On the Stigma of Mental Illness: Practical Strategies for Research and Social Change, American Psychological Association, Washington, DC.
75. Crossley, N.R. (1998) RD Laing and the British anti-psychiatry movement: a socio-historical analysis. Social Science & Medicine, 47, 877-889.
76. Crystal, S., Olfson, M., Huang, C., Pincus, H., and Gerhard, T. (2009) Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Affairs, 28, 770-781.
77. Cuijpers, P., Dekker, J., Hollon, S.D., and Andersson, G. (2009) Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: a meta-analysis. Journal of Clinical Psychiatry, 70, 1219-1229.
78. Cumyn, L., Kolar, D., Keller, A., and Hechtman, L. (2007) Current issues and trends in the diagnosis and treatment of adults with ADHD. Expert Review of Neurotherapeutics, 7, 1375-1379.
79. Cumyn, L., Hechtman, L., and French, L. (2009) Comorbidity in adults with Attention Deficit Hyperactivity Disorder (ADHD). Canadian Journal of Psychiatry, 54, 673-683.
80. Curry, J., Rohde, P., Simons, A. et al. (2006) Predictors and moderators of acute outcome in the Treatment for Adolescents With Depression Study (TADS). Journal of the American Academy of Child & Adolescent Psychiatry, 45, 1427-1439.
81. Cutler, A.J.,Montgomery, S.A., Feifel, D. et al. (2009) Extended release quetiapine fumarate monotherapy in major depressive disorder: a placeboand duloxetine-controlled study. Journal of Clinical Psychiatry, 70, 526-539.
82. Dana, J. and Loewenstein, G. (2003) A social science perspective on gifts to physicians from industry. JAMA, 290, 252-255.
83. Daughton, J.M., Padala, P.R., and Gabel, T.L. (2006) Careful monitoring for agranulocytosis during carbamazepine treatment. Journal of Clinical Psychiatry: primary care companion, 8, 310-311.
84. DeAngelis, C., Drazen, J.M., Frizelle, F.A. et al. (2004) Clinical Trial Registration: A Statement from the International Committee of Medical Journal Editors. NEJM, 351, 1250-1251.
85. Delay, J., Deniker, P., and Harl, J.-M. (1952) Utilisation en therapeutique psychiatrique d'une phenothiazine d'action. Centrale elective. Annals of Medicine and Psychology, 110, 112-131.
86. Deshauer, D. (2007) Venlafaxine (Effexor): concerns about increased risk of fatal outcomes in overdose. CMAJ, 176, 39-40.
87. DeSimoni, M.G., DeLuigi, A., Clavenna, A., and Manfridi, A. (1992) In vivo studies on the enhancement of serotonin reuptake by tianeptine. Brain Research, 574, 93-97.
88. Deussing, J.M. (2006) Animal models of depression. Drug Discovery Today: Disease Models, 3, 375-383.
89. DiMasi, J., Hansen, R., and Grabowski, H. (2003) The price of innovation: new estimates of drug development costs. Journal of Health Economics, 22, 151-185.
90. Doidge, N., Simon, B., Brauer, L. et al. (2002) Psychoanalytic patients in the U.S.,Canada, andAustralia: I.DSM-III-R disorders, indications, previous treatment, medications, and length of treatment. Journal of the American Psychoanalytic Association, 50, 575-614.
91. Dove, A. (2000) Industry support for medical centers grows. Nature Medicine, 6, 948.
92. Duffy, A. (2007) Does bipolar disorder exist in children? A selective review. Canadian Journal of Psychiatry, 52, 409-417.
93. Duffy, A., Alda, M., Hajek, T., and Grof, P. (2009) Early course of bipolar disorder in high-risk offspring: prospective study. British Journal of Psychiatry, 195, 457-458.
94. Dunbar, G.C., Perere, M.H., and Jenner, F.A. (1989) Patterns of benzodiazepine use in Great Britain as measured by a general population survey. British Journal of Psychiatry, 155, 836-841.
95. Earle, F. and Mazzacappa, E. (2002) Conduct and oppositional disorders, in Child and Adolescent Psychiatry (eds M. Rutter and E. Taylor), John Wiley & Sons, Ltd, London, pp. 419-438.
96. Eisenberg, L. (2000) Is psychiatry more mindful or brainier than it was a decade ago? British Journal of Psychiatry, 176, 1-5.
97. Elkin, I., Shea, T.,Watkins, J.T., and Imber, S.D. (1989) National Institute of Mental Health Treatment of Depression Collaborative Research Program: general effectiveness of treatments. Archives of General Psychiatry, 46, 97l-982.
98. Elliott, C. (2003) Better than Well: American Medicine Meets the American Dream, Norton, New York.
99. El-Sayeh, H.G.G. and Morganti, C. (2004) Aripiprazole for schizophrenia. Cochrane Database of Systematic Reviews, 2 (Art.No.: CD004578), DOI: 10.1002/14651858.
100. Emanuel, E.J. and Miller, F.G. (2001) The ethics of placebo-controlled trials-a middle ground. New England Journal of Medicine, 345, 915-919.
101. Engel, G.L. (1980) The clinical application of the biopsychosocial model. American Journal of Psychiatry, 137, 535-544.
102. Essali, A., Al-Haj Haasan, N., Li, C., Rathbone, J. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD000059. DOI: 10.1002/14651858.CD000059.pub2.
103. Evidence-Based MedicineWorking Group (1992) Evidence-basedmedicine: a new approach to teaching the practice of medicine. JAMA, 268, 2420-2425.
104. Faedda, G.L., Baldessarini, R.J., Glovinsky, I.P., and Austin, N.B. (2004) Pediatric bipolar disorder: phenomenology and course of illness. Bipolar Disorders, 6, 305-313.
105. Faraone, S.V. and Glatt, S.J. (2010) A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder usingmeta-analysis of effect sizes. Journal of Clinical Psychiatry Dec 29. [Epub ahead of print], 51(3), 233-241.
106. Fava, M. and Davidson, K.G. (1996) Definition and epidemiology of treatment-resistant depression. Psychiatric Clinics of North America, 19, 179-189.
107. Fava, M. and Rankin, M. (2002) Sexual functioning and SSRIs. Journal of Clinical Psychiatry, 63 (suppl 5), 13-16.
108. Fava, G.A., Ruini, C., Rafanelli, C. et al. (2004) Six-year outcome of cognitive behavior therapy for prevention of recurrent depression. American Journal of Psychiatry, 161, 1872-1876.
109. Fava, G.A. and Rush, J. (2006) Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychotherapy and Psychosomatics, 75, 139-153.
110. Fenton, M., Rathbone, J., Reilly, J., and Sultana, A. (2007) Thioridazine for schizophrenia. Cochrane Database of Systematic Reviews 3 (Art. No.: CD001944), DOI: 10.1002/14651858.CD001944.pub2.
111. Fergusson, D., Doucette, S., and Glass, K.C. (2005) Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ, 330, 396-400.
112. Fink, M. and Taylor, M.A. (2007) Electroconvulsive therapy: Evidence and challenges. JAMA, 298, 330-332.
113. Fisher, S. and Greenberg, R. (1997) From Placebo to Panacea: Putting Psychiatric Drugs to the Test, John Wiley & Sons, Inc., New York.
114. Flanagin, A. and Rennie, D. (1995) Ghostwriters: not always what they appear. Journal of the American Medical Association, 274, 870-871.
115. Fournier, J.C., DeRubeis, R.J., Hollon, S.D. et al. (2010) Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA, 303, 47-53.
116. Foussias, G. and Remington, R. (2010) Antipsychotics and schizophrenia: From efficacy and effectiveness to clinical decision-making. Canadian Journal of Psychiatry, 53, 117-125.
117. Frank, J.D. and Frank, J.B. (1991) Persuasion and Healing, 3rd edn, Johns Hopkins, Baltimore.
118. Fraser, L.M., O'Carroll, R.E., and Ebmeier, J.P. (2008) The effect of electroconvulsive therapy on autobiographical memory: A systematic review. Journal of ECT, 24, 10-17.
119. Freud, S. (1957, Originally published 1896) The aetiology of hysteria, in The Standard Edition of the Complete PsychologicalWorks of Sigmund Freud, vol. 3 (ed. and trans. J. Strachey), Hogarth Press, London, pp. 191-224.
120. Gabbard, G.O., Lazar, S.G., Hornberger, J., and Spiegel, D. (1997) The economic impact of psychotherapy: a review. American Journal of Psychiatry, 154, 147-155.
121. Gartlehner, G., Gaynes, B.N., Hansen, R.A. et al. (2008) Comparative benefits and harms of second-generation antidepressants: Background paper for the American College of Physicians. Annals of Internal Medicine, 149, 734-750.
122. Gaziano, T.A., Opie, L.H., and Weinstein, M.C. (2006) Cardiovascular disease prevention with a multi-drug regimen in the developing world: a cost-effectiveness analysis. Lancet, 368, 679-686.
123. Geddes, J.R., Sally Burgess, S., Hawton, K. et al. (2004) Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. American Journal of Psychiatry, 161, 217-222.
124. Geddes, J.R. for the BALANCE investigators and collaborators (2010) Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised openlabel trial. Lancet, 375, 385-395.
125. Geller, B., Zimerman, B., Williams, M. et al. (2002) Phenomenology of prepubertal and early adolescent bipolar disorder: examples of elated mood, grandiose behaviors, decreased need for sleep, racing thoughts and hypersexuality. Journal of Child & Adolescent Psychopharmacology, 12, 3-9.
126. Geller, B., Tillman, R., Bolhofner, K., and Zimerman, B. (2008) Child bipolar disorder: second and third episodes, predictors of 8-year outcome. Archives of General Psychiatry, 65, 1125-1133.
127. Ghaemi, S.N. (ed.) (2002) Polypharmacy in Psychiatry, Taylor and Francis, Philadelphia.
128. Ghaemi, S.N., Ko, J.Y., and Goodwin, F.K. (2002) "Cade's disease" and beyond: misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder. Canadian Journal of Psychiatry, 47, 125-134.
129. Ghaemi, S.N., Soldani, F. and Hsu, D.J. (2003) Commentary: Evidencebased pharmacotherapy of bipolar disorder. The International Journal of Neuropsychopharmacology, 6, 303-308.
130. Ghaemi, S.N., and McHugh, P.R. (2007) The Concepts of Psychiatry, John Hopkins University Press, Baltimore.
131. Ghaemi, S.N., Wingo, A.P., Filkowski, M.A., and Baldessarini, R.J. (2008) Long-term antidepressant treatment in bipolar disorder: metaanalyses of benefits and risks. Acta Psychiatrica Scandinavica, 118, 347-356.
132. Gibbons, R.D., Brown, C.H., and Hur, K. (2007) Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. American Journal of Psychiatry, 164, 1356-1363.
133. Gold, I. (2009) Reduction in psychiatry. Canadian Journal of Psychiatry, 54(8), 503-505.
134. Goldapple, K., Segal, Z., Garson, C. et al. (2004) Modulation of corticallimbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. Archives of General Psychiatry, 61, 34-41.
135. Goldberg, D. and Huxley, P. (1992) Common Mental Disorders: A Biopsychosocial Model, Tavistock Books, London.
136. Goodwin, F.K., Fireman, B., Simon, G.E. et al. (2003) Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA, 290, 1467-1473.
137. Goodwin, F.K. and Jamison, K. (2007) Manic-Depressive Illness: Bipolar Disorder and Recurrent Depression, 2nd edn, Oxford University Press, New York.
138. Gorman, J.M. (1999) Mirtazapine: clinical overview. Journal of Clinical Psychiatry, 60, 9-13.
139. Gottesman, I. and Gould, T.D. (2003) The endophenotype concept in psychiatry: etymology and strategic intentions. American Journal of Psychiatry, 160, 636-645.
140. Grad, R. (1997) More evidence linking benzodiazepines and falls. Canadian Family Physician, 43, 1367-1368.
141. Griesenbach, U., Geddes, D.M. and Alton, E.W. on behalf of the UK Cystic Fibrosis Gene Therapy Consortium (2006) Gene therapy progress and prospects: cystic fibrosis. Gene Therapy, 13, 1061-1067.
142. Groopman, J. (2007) How Doctors Think, Houghton Mifflin, New York.
143. Gunnell, D., Saperia, J. and Ashby, D. (2005) Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ, 330, 385-390.
144. Gupta, S.,Mosnik, D., Black, D.W. et al. (2004) Tardive Dyskinesia: Review of treatments past, present, and future. Annals of Clinical Psychiatry, 11, 257-266.
145. Haddad, P. (1998) The SSRI discontinuation syndrome. Journal of Psychopharmacology, 12, 305.
146. Haddad, P. (1999) Newer antidepressants and the discontinuation syndrome. Journal of Clinical Psychiatry, 58, 17-22.
147. Hadjipavlou, G., and Yatham, L.N. (2008) Mood stabilizers in the treatment of bipolar II disorder, in Bipolar II Disorder: Modelling, Measuring and Managing (ed. G. Parker) Cambridge University Press, Cambridge, pp. 120-137.
148. Hansen, R., Gaynes, B., Thieda, P. et al. (2008) Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. Psychiatric Services, 59, 1121-1130.
149. Hatala, R., Keitz, S., Wyer, P., and Guyatt, G. (2005) Tips for learners of evidence-based medicine: 4. Assessing heterogeneity of primary studies in systematic reviews and whether to combine their results. Canadian Medical Association Journal, 172, 661-665.
150. Hawton, K., Zahl, D. andWeatherall, R. (2003) Suicide following deliberate self-harm: long-term follow-up of patients who presented to a general hospital. Brit J Psychiatry, 182, 537-542.
151. Healy, D. (1997) The Antidepressant Era, Harvard University Press, Cambridge, MA.
152. Healy, D. (1998) Pioneers in psychopharmacology. International Journal of Neuropsychopharmacology, 1, 191-194.
153. Healy, D. (2002) The Creation of Psychopharmacology, Harvard University Press, Cambridge, MA.
154. Healy, D. (2004) Let Them Eat Prozac: The Unhealthy Relationship between the Pharmaceutical Industry and Depression, New York University Press, New York.
155. Healy, D. (2008) Mania: A Short History of Bipolar Disorder, Johns Hopkins University Press, Baltimore.
156. Healy, D. (2009) Psychiatric Drugs Explained, 5th edn, Elsevier, London.
157. Healy, D., and Cattell, D. (2003) Interface between authorship, industry and science in the domain of therapeutics. British Journal of Psychiatry, 183, 22-27.
158. Healy, D., and Thase, M. (2003) Is academic psychiatry for sale? British Journal of Psychiatry, 182, 388-390.
159. Hechtman, L., Abikoff, H., Klein, R.G. et al. (2004) Academic achievement and emotional status of children with ADHD treated with long-term Methylphenidate and multimodal psychosocial treatment. Journal of the American Academy of Child and Adolescent Psychiatry, 43, 812-819.
160. Heninger, G.R., Delgado, P.L., Charney, D.S., and Hirschfeld, R.M. (1996) The revised monoamine theory of depression. Pharmacopsychiatry, 29, 2-11.
161. Henry, C., Mitropoulou, V., New, A.S. et al. (2001) Affective instability and impulsivity in borderline personality and bipolar II disorders: similarities and differences. Journal of Psychiatric Research, 35, 307-312.
162. Heres, S., Davis, J., Maino, K. et al. (2006) Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of secondgeneration antipsychotics. American Journal of Psychiatry, 163, 185-194.
163. Heyman, I., and Fineberg, N.A. (2006) Obsessive-compulsive disorder. BMJ, 333, 424-429.
164. Hirschfeld, R.M. (1999) Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs. Journal of Clinical Psychiatry, 60, 326-335.
165. Hodges, B. (1995) Interactions with the pharmaceutical industry: experiences and attitudes of psychiatry residents, interns and clerks. CMAJ, 153, 553-559.
166. Holbrook, A.M., Crowther, R., Lotter, A. et al. (2000) Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ, 62.
167. Horwitz, A.V., and Wakefield, J.C. (2007) The Loss of Sadness: How Psychiatry Transformed Normal Sorrow into Depressive Disorder, Oxford University Press, New York.
168. Inskip, H.M., Harris, E.C., and Barraclough, B. (1998) Lifetime risk of suicide for affective disorder, alcoholism and schizophrenia. British Journal of Psychiatry, 172, 35-37.
169. Insel, T., and Quirion, R. (2005) Psychiatry as a clinical neuroscience discipline. JAMA: the journal of the American Medical Association, 294, 2221-2224.
170. Ioannidis, J.P.A. (2005) Why most published research findings are false. PLoS Med, 2 (8), e124.
171. Jayaram, M.B., Hosalli, P., and Stroup, S. (2006) Risperidone versus olanzapine for schizophrenia. Cochrane Database of Systematic Reviews 2 (Art. No.: CD005237), DOI: 10.1002/14651858.CD005237.pub2.
172. Jensen, P.S., Martin, D., and Cantwell, D.P. (1997) Comorbidity in ADHD: Implications for Research, Practice, andDSM-V. Journal of the American Academy of Child & Adolescent Psychiatry, 36, 1065-1079.
173. Jones, P.B., Barnes, T.R.E., Davies, L. et al. (2006) Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry, 63, 1079-1087.
174. Jones, S. (2004) Psychotherapy of bipolar disorder: a review. Journal of Affective Disorders, 80, 101-114.
175. Joy, C.B., Adams, C.E., and Lawrie, S.M. (2006) Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 4 (Art. No.: CD003082), DOI: 10.1002/14651858.CD003082.pub2.
176. Judd, L.L., and Akiskal, H.S. (2003) The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. Journal of Affective Disorders, 73, 123-131.
177. Judd, L.L., Schettler, P.J., Akiskal, H.S. et al. (2008) Residual symptom recovery from major affective episodes in bipolar disorders and rapid episode relapse/recurrence. Archives of General Psychiatry, 65, 386-394.
178. Juergens, S.M. (1993) Benzodiazepines and addiction. Psychiatric clinics of North America, 16 (11), 75-86.
179. Jureidini, J.N., Doecke, C.J., Mansfield, P.R. et al. (2004) Efficacy and safety of antidepressants for children and adolescents. BMJ, 328, 879-883.
180. Kaymaz, N., Vanos, J., Loonen, A., and Nolen, W.A. (2008) Evidence that patients with single versus recurrent depressive episodes are differentially sensitive to treatment discontinuation: a meta-analysis of placebo-controlled randomized trials. Journal of Clinical Psychiatry, 69, 1423-1436.
181. Kazdin, A.E. (2005) Parent Management Training: Treatment for Oppositional, Aggressive, and Antisocial Behavior in Children and Adolescents, Oxford University Press, New York.
182. Keck, P.E. Jr., McElroy, S.L., Strakowski, S.M., and Soutullo, C.A. (2000) Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. Journal of Clinical Psychiatry, 61 (suppl. 4), 33-38.
183. Kendler, K.S. (2005) Psychiatric genetics: A methodologic critique. American Journal of Psychiatry, 162, 3-11.
184. Kendler, K.S., and Gardner, C.O. (1998) Boundaries of major depression: An evaluation of DSM-IV criteria. American Journal of Psychiatry, 155, 172-177.
185. Kendler, K.S., and Prescott, C.A. (2006) Genes, Environment, and Psychopathology: Understanding the Causes of Psychiatric and Substance Use Disorders, Guilford Press, New York.
186. Kerwin, R. (2007) When should clozapine be initiated in schizophrenia? Some arguments for and against earlier use of clozapine. CNS Drugs, 21, 267-278.
187. Kessler, R.C., Merikangas, K.R., Berglund, P. et al. (2003) Mild disorders should not be eliminated from the DSM-V. Archives of General Psychiatry, 60, 1117-1122.
188. Kessler, R.C., Chiu,W.T., Demler, O. et al. (2005a) Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry, 62, 617-627.
189. Kessler, R.C., Coccaro, E.F., Fava, M. et al. (2006a) The prevalence and correlates of DSM-IV Intermittent Explosive Disorder in the National Comorbidity Survey Replication. Archives of General Psychiatry, 63, 669-678.
190. Kessler, R.C., Adler, L., Barkley, R. et al. (2006b) The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey replication. American Journal of Psychiatry, 163, 716-723.
191. Ketter, T.A. (2009) Combination therapy versus monotherapy in bipolar disorder. Journal of Clinical Psychiatry, 69, e34.
192. Khan, A., Khan, S., Kolts, R., and Brown, W.A. (2003) Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. American Journal of Psychiatry, 160, 790-792.
193. Kirsch, I. (2009) The Emperor's New Drugs: Exploding the Antidepressant Myth, Random House, London.
194. Kirsch, I., Deacon, B.J., Huedo-Medina, T.B. et al. (2008) Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med, 5, e45.
195. Klein,D.F. (1978) Aproposed definition ofmental disorder, in Critical Issues in Psychiatric Diagnosis (eds D.F. Klein and R.L. Spitzer), Raven Press, New York, pp. 41-72.
196. Klein, D.N., and Santiago, N.J. (2003) Dysthymia and chronic depression: introduction, classification, risk factors, and course. Journal of Clinical Psychology, 59, 807-816.
197. Klerman, G.L. (1990) The psychiatric patient's right to effective treatment: implications of Osheroff v. Chestnut Lodge. American Journal of Psychiatry, 147, 409-418.
198. Klerman, G.L., DiMascio, A., Weissman, M.M. et al. (1974) Treatment of depression by drugs and psychotherapy. American Journal of Psychiatry, 131, 186-191.
199. Kocsis, J.H. (2003) Pharmacotherapy for chronic depression. Journal of Clinical Psychology, 59, 885-892.
200. Kocsis, J.H., Gelenberg, A.J., Rothbaum, B.O., and Klein, D.N. (2009) Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: The REVAMP Trial. Archives of General Psychiatry, 66, 1178-1188.
201. Koenigsberg, H.W., Harvey, P.D., Mitropoulou, V., Schmeidler, J., New, A.S., Goodman, M., et al. (2002) Characterizing affective instability in borderline personality disorder. American Journal of Psychiatry, 159, 784-788.
202. Koenigsberg, H. (in press) Affective instability: toward an integration of neuroscience and psychological perspectives. Journal of Personality Disorders., 24(1), 60-82.
203. Kollins, S.H., Epstein, J.N., and Conners, C.K. (2004) Conners' Rating Scales-Revised, in The Use of Psychological Testing for Treatment Planning and Outcomes Assessment: Volume 2: Instruments for Children and Adolescents, 3rd edn (ed. M.E. Maruish), Laurence Erlbaum, Mahwah, NJ, pp. 215-233.
204. Kollins, S.H., Epstein, J.N., Conners, C.K. (2006) Conners Rating Scale Revised, in M.E. Maruish, TheUse of Psychological Testing for Treatment Planning and Outcomes, New York, Routledge.
205. Kowatch, R.A., Fristad, M.A., Birmaher, B. et al. (2005) Treatment guidelines for children and adolescents with bipolar disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 44, 213-235.
206. Kraepelin, E. (1921) Manic-Depressive Insanity and Paranoia (Trans. R.M. Barclay, ed. G.M. Robertson), E and S Livingstone, Edinburgh (Original published 1913).
207. Kramer, P. (1993) Listening to Prozac, Viking, New York.
208. Krueger, R.F. (1999) The structure of common mental disorders. Archives of General Psychiatry, 56, 921-926.
209. Kuhn, R. (1958) The treatment of depressive states withG22355 (imipramine hydrochloride). American Journal of Psychiatry, 115, 459-464.
210. Kupfer, D.J., First, M., and Regier, D. (2005) A Research Agenda for DSM-V, American Psychiatric Press, Washington DC.
211. Kutcher, S.P. (1997) Practitioner review: The pharmacotherapy of adolescent depression, Journal of Child Psychology and Psychiatry, 38 (7), 755-767.
212. Laine, C., Horton, R., DeAngelis, C.D., and Drazen, J.M. (2007) Clinical trial registration: looking back and moving ahead. CMAJ, 177, 1.
213. Lambert, M. (2003) Bergin and Garfield's Handbook of Psychotherapy and Behavior Change, John Wiley & Sons, Inc., New York.
214. LeCarre, J. (2001) The Constant Gardener, Hodder & Stoughton, London.
215. Lee, P.E., Gill, S.S., Freedman, M. et al. (2004) Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ, 329, 75-78.
216. Lehmann, H.E. (1993) Before they called it psychopharmacology. Neuropsychopharmacology, 8, 291-303.
217. Lehmann, H.E., and Hanrahan,G.E. (1954) Chlorpromazine, a newinhibiting agent for psychomotor excitement and manic states. American Medical Association Archives of Neurology and Psychiatry, 71, 227-237.
218. Lenzenweger, M.F., Lane, M.C., Loranger, A.W., and Kessler, R.C. (2007) DSM-IV Personality Disorders in theNationalComorbidity Survey Replication. Biological Psychiatry, 62, 553-556.
219. Leucht, S., Wahlbeck, K., Hamann, J., and Kissling, W. (2003) New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet, 361, 1581-1589.
220. Leucht, S., Kissling, W., and Davis, J.M. (2009) Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychological Medicine, 39, 1603-1606.
221. Lewis, S., and Lieberman, J.A. (2008) CATIE and CUtLASS: can we handle the truth? British Journal of Psychiatry, 192, 161-163.
222. Lexchin, J., Bero, L.A., Djulbegovic, B., and Clark, O. (2003) Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ, 326, 1167-1170.
223. Lexchin, J., and Light, D.W. (2006) Commercial influence and the content of medical journals. BMJ, 332, 1444-1447.
224. Lieberman, J.A., Stroup, T.S., McEvoy, J.P. et al. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353, 1209-1223.
225. Linehan, M.M. (1993) Dialectical Behavior Therapy for Borderline Personality Disorder. New York: Guilford.
226. Lisman, J.E., Coyle, J.T., Green, R.W. et al. (2008) Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends in Neuroscience, 31, 234-242.
227. Lundahl, B., Risser, H.B., and Lovejoy, M.C. (2006) A meta-analysis of parent training: Moderators and follow-up effects. Clinical Psychology Review, 26, 86-104.
228. Macaskill, N., and Geddes, J. (1991) DSM-III in the training of British psychiatrists: a national survey. International Journal of Social Psychiatry, 37, 182-186.
229. Macritchie, K., Geddes, J., Scott, J. et al. (2001) Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database of Systematic Reviews 3 (Art. No.: CD003196), DOI: 10.1002/14651858.CD003196.
230. MacGillivray, S., Arroll, B., Hatcher, S., and Ogston S. (2003) Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ, 326, 1014-1017.
231. Mannuzza, S., and Klein, R.G. (2000) Long-term prognosis in attentiondeficit/ hyperactivity disorder. Child and Adolescent Psychiatric Clinics of North America, 9, 711-726.
232. March, J.S., and Vitello, B. (2009) Clinical messages from the Treatment for Adolescents with Depression Study (TADS). American Journal of Psychiatry, 166, 1118-1123.
233. Marcus, R.N., McQuade, R.D., and Carson, W.H. (2008) The efficacy and safety of aripiprazole as adjunctive therapy inmajor depressive disorder.A second, multicenter, randomized, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology, 28, 156-165.
234. Maremmani, I., Perugi, G., Pacini, M., and Akiskal, H. (2006) Toward a unitary perspective on the bipolar spectrum and substance abuse: Opiate addiction as a paradigm. Journal of Affective Disorders, 93, 1-12.
235. Margolese, H.,Chouinard,G.,Kolivakis, T. et al. (2005) Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: Pathophysiology and mechanisms of induction. Canadian Journal of Psychiatry, 50, 541-547.
236. Martinez, C., Rietbrock, S., Wise, L. et al. (2005) Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ, 330, 389-394.
237. May, P.R. (1968) Treatment of Schizophrenia, Science House, New York.
238. Mayor, S. (2003) Nature group extends rules on disclosure to review authors. BMJ, 327, 829.
239. McAlister, F.A. (2008) The "number needed to treat" turns 20 - and continues to be used and misused. Canadian Medical Association Journal, 179, 549-555.
240. McGee, R.A., Clark, S.E., and Symons, D.K. (2000) Does the Conners' continuous performance test aid in ADHD diagnosis? Journal of Abnormal Child Psychology, 28, 415-424.
241. McNally, R.J. (1999) Post-traumatic stress disorder, in Oxford Textbook of Psychopathology (eds T. Millon, P. Blaney and R. Davis), Oxford University Press, New York, pp. 144-165.
242. Meaney, M.J., and Szyf, M. (2005) Environmental programming of stress responses throughDNAmethylation: life at the interface between a dynamic environment and a fixed genome. Dialogues in Clinical Neuroscience, 7, 103-123.
243. Meltzer, H.Y., Alphs, L., Green, A.I., Altamura, A.C., Anand, R., Bertoldi, A., Bourgeois, M., Chouinard, G., Islam, M.Z., Kane, J., Krishnan, R., Lindenmayer, J.P., Potkin, S. for the InterSePT Study Group (2003) Clozapine treatment for suicidality in schizophrenia International Suicide Prevention Trial (InterSePT) Arch Gen Psychiatry, 60, 82-91.
244. Merikangas, K.R., Akiskal, H.S., Angst, J. et al. (2007) Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Archives of General Psychiatry, 64, 543-552.
245. Middleton, H., Shaw, I., and Feder, G. (2005) NICE guidelines for the management of depression. British Medical Journal, 330, 267-268.
246. Miller, E.K., and Cohen, J.D. (2001) An integrative theory of prefrontal cortex function. Annu Rev Neurosci, 24, 167-202.
247. Miller, W.R., and Carroll, K. (2006) Rethinking Substance Abuse: What the Science Shows, and What We Should Do about It, Guilford Press, New York.
248. Mintzes, B., Morris, L., Barer, R., Kravitz, L., Kazanjian, A., Bassett, K., Lexchin, J., Evans, R.G., Pan, R., Marion, S.R. (2002) Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey. BMJ 324, 278-279.
249. Mitchell, A.J., Bae, A., and Rao, S. (2009) Clinical diagnosis of depression in primary care: a meta-analysis. Lancet, 374, 609-619.
250. Moeller, F.G.,Barratt, E.S.,Dougherty, D.M. et al. (2001) Psychiatric aspects of impulsivity. American Journal of Psychiatry, 158, 1783-1793.
251. Mojtabai, R., and Olfson, M. (2010) National trends in psychotropic medication polypharmacy in office-based psychiatry. Archives of General Psychiatry, 67, 26-36.
252. Moncrieff, J., Wessely, S., Hardy, R. (2004) Active placebos versus antidepressants for depression. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD003012. DOI: 10.1002/14651858.CD003012.pub2.
253. Moncrieff, J. (2008) The Myth of the Chemical Cure, Palgrave Macmillan.
254. Moncrieff, J. (2009) A critique of the dopamine hypothesis of schizophrenia and psychosis. Harvard Review of Psychiatry, 17, 214-225.
255. Moncrieff, J., Wessely, S., and Hardy, R. (2004) Active placebos versus antidepressants for depression. Cochrane Database of Systematic Reviews 1 (Art. No.: CD003012), DOI: 10.1002/14651858.CD003012.pub2.
256. Moncrieff, J., and Kirsch, I. (2005) Efficacy of antidepressants in adults. BMJ, 331, 155-157.
257. Moncrieff, J., and Cohen, D. (2009) How do psychiatric drugs work? BMJ, 338, 1963.
258. Monroe, S.M., and Simons, A.D. (1991) Diathesis-stress theories in the context of life stress research. Psychological Bulletin, 110, 406-425.
259. Montori, V.M., Kleinbart, J., Newman, T.B. et al. (2004) Tips for learners of evidence-basedmedicine: 2. Measures of precision (confidence intervals). Can. Med. Assoc. J., 171, 611-615.
260. Moran, M. (2008) Senator wants APA records of drug-industry interactions. Psychiatric News, 43 (16), 1.
261. Moreno, C., Laje, G., Blanco, C. et al. (2007) National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Archives of General Psychiatry, 64, 1032-1039.
262. Morgan,A.E., Hynd,G.W.,Riccio, C.A., and Hall, J. (1996) Validity ofDSMIV ADHD predominantly inattentive and combined types: relationship to previous DSM. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 325-333.
263. Morgan, J.R. (2002) Review: psychological treatment is as effective as antidepressants for bulimia nervosa, but a combination is best. Evidence Based Mental Health, 5, 75.
264. Mojtabai, R., and Olfson, M. (2008) National trends in psychotherapy by office-based psychiatrists. Archives of General Psychiatry, 65, 962-970.
265. Moynihan, R., Heath, I., and Henry, D. (2002) Selling sickness: the pharmaceutical industry and disease mongering. BMJ, 324, 886-891.
266. Mulder, R.T. (2008) An epidemic of depression or the medicalization of distress? Perspectives in Biology and Medicine, 51, 238-250.
267. Murphy, B.P., Chung, Y.-C., Park, T.-W., and McGorry, P.D. (2006) Pharmacological treatment of primary negative symptoms in schizophrenia: A systematic review. Schizophrenia Research, 88, 5-25.
268. National Institute for Health and Clinical Excellence (2006) Themanagement of bipolar disorder in adults, children and adolescents, in primary and secondary care. Accessed online, June 2009.
269. National Institute for Health and Clinical Excellence (2007) Depression: management of depression in primary and secondary care. Accessed online, June 2009.
270. National Institute for Health and Clinical Excellence (2008) Attention deficit hyperactivity disorder: Diagnosis and management of ADHD in children, young people and adults. Accessed online, June 2009.
271. National Institute for Health and Clinical Excellence (2009) Schizophrenia Core interventions in the treatment and management of schizophrenia in primary and secondary care (update). Accessed online, May 2009.
272. Nelson, J.C., Thase, M.E., and Khan, A. (2008) Are antidepressants effective?-what's a clinician to think? Journal of Clinical Psychiatry, 69, 1014-1015.
273. Nelson, J.C., and Papakostas, G.I. (2009) Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. American Journal of Psychiatry, 166, 980-991.
274. Nemeroff,C.B. (2005) Use of atypical antipsychotics in refractory depression and anxiety. Journal of Clinical Psychiatry, 66 (suppl 8), 13-21.
275. Nemeroff, C.B., and Owens, M.J. (2002) Treatment of mood disorders. Nature Neuroscience, 5 (suppl), 1068-1070.
276. Nemeroff, C.B., and Owens, M.J. (2003) Reply to 'Editorial policies on financial disclosure". Nature Neuroscience, 6, 1000-1001.
277. Nemeroff, C.B., Heim, C.M., Thase, M.E. et al. (2003) Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. PNAS, 100, 14293-14296.
278. Nemeroff, C.B., Lieberman, J.A.,Weiden, P.J. et al. (2005) From clinical research to clinical practice: a 4-year reviewof ziprasidone. CNS Spectrums, 10 (Suppl 17), 1-20.
279. Nemeroff, C.B., Mayberg, H., Krahl, S.E. et al. (2006) VNS therapy in treatment-resistant depression: clinical evidence and putative neurobiological mechanisms. Neuropsychopharmacology, 31, 1345.
280. Neville, H.J., and Bavelier, D. (2000) Specificity and plasticity in neurocognitive development in humans, in The New Cognitive Neurosciences, 2nd edn (ed. M.S. Gazzaniga), The MIT Press, Cambridge, MA, pp. 83-99.
281. Newcomer, J.W., and Haupt, D.W. (2006) The metabolic effects of antipsychotic medication. Canadian Journal of Psychiatry, 51, 480-491.
282. Newton-Howes, G., Tyrer, P., and Johnson, T. (2006) Personality disorder and the outcome of depression: meta-analysis of published studies. British Journal of Psychiatry, 188, 13-20.
283. Norman, T., and McGrath, C. (2000) Stress induced animal models of depression. Stress Medicine, 16, 195-197.
284. O'Brien, C.P. (2005) Benzodiazepine use, abuse, and dependence. Journal of Clinical Psychiatry, 66 (Suppl 2), 28-33.
285. Ohgami, H., Terao, T., Shiotsuki, I. et al. (2009) Lithium levels in drinking water and risk of suicide. British Journal of Psychiatry, 194, 464-465.
286. Olfson, M., Marcus, S.C., Tedeschi, M., and Wan, G.J. (2006) Continuity of antidepressant treatment for adults with depression in the United States. American Journal of Psychiatry, 163, 101-108.
287. Olfson, M., and Marcus, S.C. (2009) National patterns in antidepressant medication treatment. Archives of General Psychiatry, 66, 848-856.
288. Olivieri, N. (2003) Patients' health or company profits? The commercialisation of academic research. Science and Engineering Ethics, 9, 29-41.
289. Osler, W. (1898) The Principles and Practice of Medicine, Applelton, New York.
290. Otto, M.W., Smiths, J.A.J., and Reese, H.E. (2005) Combined psychotherapy and pharmacotherapy for mood and anxiety disorders in adults: review and analysis. Clinical Psychology: Science and Practice, 12, 72-86.
291. Owens, E.B., Hinshaw, S.P., and Arnold, L.E. (2003) Which treatment for whom with ADHD? Moderators of treatment response in the MTA. Journal of Consulting and Clinical Psychology, 71, 540-552.
292. Papakostas, G.I., and Shelton, R.C. (2008) Use of atypical antipsychotics for treatment-resistant major depressive disorder. Current Psychiatry Reports, 10, 481-486.
293. Parikh, S., LeBlanc, S.R., and Ovanessian, M. (in press) Advancing bipolar disorder: key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Canadian Journal of Psychiatry.
294. Paris, J. (2005) The Fall of an Icon: Psychoanalysis and Academic Psychiatry, University of Toronto Press, Toronto, Ontario, Canada.
295. Paris, J. (2006) Predicting and Preventing Suicide: Do We Know Enough to Do Either? Harvard Review of Psychiatry, 14, 233-240.
296. Paris, J. (2008a) Prescriptions for the Mind, Oxford University Press, New York.
297. Paris, J. (2008b) Treatment of Borderline Personality Disorder: A Guide to Evidence-Based Practice, Guilford Press, New York.
298. Paris, J. (2008c) Clinical trials in personality disorders. Psychiatric Clinics of North America, 31, 517-526.
299. Paris, J. (2009) A critique of the bipolar spectrum. Harvard Review of Psychiatry, 17, 206-213.
300. Paris, J. (in press) Estimating the prevalence of personality disorders in the community. Journal of Personality Disorders.
301. Paris, J., Gunderson, J.G., and Weinberg, I. (2007) The interface between borderline personality disorder and bipolar spectrum disorder. Comprehensive Psychiatry, 48, 145-154.
302. Parker, G. (2000) The nature of bipolar depression: implications for the definition of melancholia. Journal of Affective Disorders, 59, 217-224.
303. Parker, G. (2001) New and old antidepressants: all equal in the eyes of the lore? British Journal of Psychiatry, 179, 95-96.
304. Parker, G. (2005) Beyond major depression. Psychological Medicine, 35, 467-474.
305. Parker, G. (ed.) (2008) Bipolar-II Disorder: Modelling, Measuring and Managing, Cambridge University Press, Cambridge, UK.
306. Parker, G. (2009) Antidepressants on trail: how valid is the evidence? British Journal of Psychiatry, 193, 1-3.
307. Parker, G., Hadzi-Pavlovic, D., and Pedic, F. (1992) Psychotic (delusional) depression: a meta-analysis of physical treatments. Journal of Affective Disorders, 24, 17-24.
308. Parker, G., and Parker, K. (2003) Which antidepressants flick the switch? A review. Australian and New Zealand Journal of Psychiatry, 37, 464-468.
309. Parker, G., and Manicavasagar, V. (2005) Modelling and Managing the Depressive Disorders: A Clinical Guide, Cambridge University Press, Cambridge, UK.
310. Patten, S.B. (2008) Major depression prevalence is high, but the syndrome is a poor proxy for community populations' clinical needs. Canadian Journal of Psychiatry, 53, 411-419.
311. Patten, S.B., and Beck, C.A. (2004) Major Depression and Mental Health Care Utilization in Canada: 1994 to 2000. Canadian Journal of Psychiatry, 48, 303-310.
312. Patten, S.B., and Paris, J. (2008) The bipolar spectrum-a bridge too far? Canadian Journal of Psychiatry, 53, 762-768.
313. Pelham, W.E., and Fabian, G.A. (2008) Evidence-based psychosocial treatment for ADHD: An update. Journal of Clinical Child and Adolescent Psychology, 37, 184-214.
314. Pelkonen, M., and Marttunen, M. (2003) Child and adolescent suicide: epidemiology, risk factors, and approaches to prevention. Paediatric Drugs, 5, 243-265.
315. Pepper, C.M., Klein, D.N., Anderson, R.L. et al. (1995) DSM-III-R Axis II comorbidity in dysthymia and major depression. American Journal of Psychiatry, 152, 239-247.
316. Perlis, R.H., Perlis, C.S., Wu, Y. et al. (2005) Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatry, 162, 1957-1960.
317. Perugi, G., and Akiskal, H.S. (2002) The soft bipolar spectrum redefined: focus on the cyclothymic, anxious-sensitive, impulse-dyscontrol, and bingeeating connection in bipolar II and related conditions. Psychiatric Clinics North America, 25, 713-737.
318. Pini, S., de Queiroz, V., Pagnin, D. et al. (2005) Prevalence and burden of bipolar disorders in European countries. European Neuropsychopharmacology, 15, 425-434.
319. Plomin, R., DeFries, J.C., McClearn, G.E., and Rutter, M.M. (2000) Behavioral Genetics: A Primer (3rd ed.). New York: W.H. Freeman.
320. Preskorn, S.H., and Lacey, R.L. (2007) Polypharmacy: When is it rational? Journal of Psychiatric Practice, 13, 97-105.
321. Qaseem, A., Snow, V., Denberg, T.D. et al. (2008) Using second-generation antidepressants to treat depressive disorders: A clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 149, 725-733.
322. Rane, A. (2001) Postgenomic prospects of success in drug development and pharmacotherapy. Nature, The Pharmacogenomics Journal, 1, 6-9.
323. Ray, W.A., Chung, C.P., Murray, K.T. et al. (2009) Atypical antipsychotic drugs and the risk of sudden cardiac death. NEJM, 360, 225-235.
324. Raz, A. (2006) Perspectives on the efficacy of antidepressants for child and adolescent depression. PLoS Med, 3 (1), e9.
325. Rapoport, J.L., Buchsbaum, M.S., Zahn, T.P. et al. (1978) Dextroamphetamine: cognitive and behavioral effects in normal prepubertal boys. Science, 199, 560-563.
326. Regier, D.A., Wilk, J., West, J.C., and Duffy, F.F. (2003, May) Current status of the psychiatry workforce in the United States. Presented at the American Psychiatric Association, San Francisco.
327. Rickels, K., Amsterdam, J.D., Clary, C. et al. (1991) Buspirone in major depression: a controlled study. Journal of Clinical Psychiatry, 52, 34-38.
328. Riederer, P., Lachenmayer, L., Laux, G. (2004) Clinical Applications of MAO-Inhibitors, Current Medicinal Chemistry, 11(15), 2033-2044.
329. Risch, N., Herrell, R., Lehner, T. et al. (2009) Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: A meta-analysis. JAMA, 301, 2462-2471.
330. Rissmiller, D., and Rissmiller, J.H. (2006) Evolution of the antipsychiatry movement into mental health consumerism. Hospital & Community Psychiatry, 57, 863-866.
331. Robins, L. (1966) Deviant Children Grown Up. Baltimore, Williams and Wilkins.
332. Robins, E., and Guze, S.B. (1970) Establishment of diagnostic validity in psychiatric illness: its application to schizophrenia. American Journal of Psychiatry, 126, 107-111.
333. Rothman, D.J., McDonald, W.J., Berkowitz, C.D. et al. (2009) Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA, 301, 1367-1372.
334. Rubinow, D.R. (2006) Depression - augmentation or switch after initial SSRI treatment. NEJM 354, 2611-2613.
335. Rush, A.J., Fava, M., Wisniewski, S.R. et al. (2004) Sequenced Treatment Alternatives to Relieve Depression (STAR*D): rationale and design. Controlled Clinical Trials, 25, 119-142.
336. Rush, A.J., Trivedi, M.H., Wisniewski, S.R. et al. (2006a) STAR*D Study Team: Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. New England Journal of Medicine, 354, 1231-1242.
337. Rush, A.J.,Wisniewski, S.R., Nierenberg, A.A. et al. (2006b) A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. American Journal of Psychiatry, 163, 1161-1172.
338. Russell, J., Moskowitz, D., Sookman, D. et al. (2007) Affective instability in patients with borderline personality disorder. J Abnormal Psychology, 116, 578-588.
339. Rutter, M. (2006) Genes and Behavior: Nature-Nurture Interplay Explained, Blackwell, London.
340. Ryan, N.D., Puig-Antich, J., Ambrosini, P. et al. (1987) The clinical picture of major depression in children and adolescents. Archives of General Psychiatry, 44, 854-861.
341. Schachar, R., and Tannock, R. (2002) Syndromes of hyperactivity and attention deficit, in Child and Adolescent Psychiatry (eds M. Rutter and E. Taylor), John Wiley & Sons, Ltd, London, pp. 399-418.
342. Scherk, H., Pajonk, F.G., and Leucht, S. (2007) Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Archives of General Psychiatry, 64, 442-455.
343. Schillevoort, I., de Boer, A., Herings, R.M. et al. (2001) Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine. The Annals of Pharmacotherapy, 35, 1517-1522.
344. Schneider, L.S., Dagerman, K.S., and Insel, P. (2005) Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials. JAMA, 294, 1934-1943.
345. Schuchman, M. (2005) The Drug Trial: Nancy Olivieri and the Science Scandal that Rocked the Hospital for Sick Children, Random House, New York.
346. Scott, A., Davidson, A., and Palmer, K. (2001) Antidepressant drugs in the treatment of anxiety disorders. Advances in Psychiatric Treatment, 7, 275-282.
347. Scott, J., Paykel, E., Morriss, R. et al. (2006) Cognitive-behavioural therapy for severe and recurrent bipolar disorders: randomised controlled trial. British Journal of Psychiatry, 188, 313-320.
348. Seeman, P., Lee, T., Chau-Wong, M., and Wong, K. (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature, 261, 717-719.
349. Seeman, P., and Kapur, S. (2000) Schizophrenia: More dopamine, more D2 receptors. PNAS, 97, 7673-7675.
350. Shapiro, J.R., Berkman, N.D., Brownley, K.A. et al. (2007) Bulimia nervosa treatment: A systematic review of randomized controlled trials. International Journal of Eating Disorders, 40, 321-336.
351. Shekelle, P., Maglione, M., Bagley, S. et al. (2007) Efficacy and comparative effectiveness of off-label use of atypical antipsychotics. Comparative Effectiveness Review No. 6. Rockville, MD: Agency for Healthcare Research and Quality. http://www.rand.org/he (accessed December 2009).
352. Shelton, C.I. (2004) Long-term management of major depressive disorder: are differences among antidepressant treatments meaningful? Journal of Clinical Psychiatry, 65 (Suppl 17), 29-33.
353. Shepherd, G.M. (1998) The Synaptic Organization of the Brain, Oxford University Press, New York.
354. Shorter, E. (2009) Before Prozac: the Troubled History of Mood Disorders in Psychiatry, Oxford University Press, New York.
355. Shorter, E., and Healy, D. (2007) Shock Therapy: A History of Electroconvulsive Treatment in Mental Illness, Rutgers University Press, New Brunswick, N.J.
356. Singh, M.K., DelBello, M.P., Stanford, K.E. et al. (2007) Psychopathology in children of bipolar parents. Journal of Affective Disorders, 102, 131-136.
357. Sng, J., Meaney, M.J. (2009) Environmental regulation of the neural epigenome. Epigenomics, 1, 131-151.
358. Srisurapanont, M., Maneeton, B., and Maneeton, N. (2004) Quetiapine for schizophrenia. Cochrane Database of Systematic Reviews 2 (Art. No.: CD000967), DOI: 10.1002/14651858.CD000967.pub2.
359. Stein, D.J., Seedat, S., Iversen, A., and Wessley, S. (2007) Post-traumatic stress disorder: medicine and politics. Lancet, 369, 139-144.
360. Stiles,W.B., Barkham, M., Twigg, E. et al. (2006) Effectiveness of cognitivebehavioural, person-centred and psychodynamic therapies as practised in UK National Health Service settings. Psychological Medicine, 36, 555-566.
361. Smith, M.L., Glass, G.V., and Miller, T. (1980) The Benefits of Psychotherapy, Johns Hopkins Press, Baltimore.
362. Stafford, R.S. (2008) Regulating off-label drug use-rethinking the role of the FDA. NEJM, 358, 1427-1429.
363. Stone, M., Laughren, T., Jones, L., Levenson, M., Holland, C., Hugh, A., Hammad, T.A., Temple, R., Rochester, G. (2009) Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ, 339, b2880.
364. Summerfelt, W.T., and Meltzer, H.Y. (1998) Efficacy vs. effectiveness in psychiatric research. Psychiatric Services, 49, 834.
365. Suppes, T.,Vieta, E., Liu, S. et al. (2009) Investigatorsmaintenance treatment for patients with bipolar I disorder: results from a NorthAmerican study of quetiapine in combination with lithium or divalproex. American Journal of Psychiatry, 166, 476-488.
366. Susman, E.J., and Rogol, A. (2004) Handbook of Adolescent Psychology, John Wiley & Sons, Ltd, London.
367. Tamminga, C., and David, J.M. (2007) The neuropharmacology of psychosis. Schizophrenia Bulletin, 33, 937-946.
368. Tang, T.Z.,DeRubeis, R.J., Hollon, S.D. et al. (2009) Personality change during depression treatment: A placebo-controlled trial. Archives of General Psychiatry, 66, 1322-1330.
369. Tantam,D. (2006) Psychotherapy in the UK: Results of a survey of registrants of the United Kingdom Council for Psychotherapy. European Journal of Psychotherapy, Counselling & Health, 8, 321-342.
370. Tarrier, N. (2005) Cognitive behaviour therapy for schizophrenia - a review of development, evidence and implementation. Psychotherapy & Psychosomatics, 74, 136-144.
371. Taylor, D. (1989) Current usage of benzodiazepines in Britain. British Journal of Addiction, 84, 541-546.
372. Thase, M.E. (2008) Do antidepressants really work? A clinicians' guide to evaluating the evidence. Current Psychiatry Reports, 10, 487-494.
373. Thase, M.E., Entsuah, A.R., and Rudolph, R.L. (2001) Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. British Journal of Psychiatry, 178, 234-241.
374. Thase, M.E., and Jindal, R.D. (2003) Combining psychotherapy and psychopharmacology for treatment of mental disorders, in Handbook of Psychotherapy and Behavior Change (ed. M. Lambert), John Wiley & Sons, Inc., New York, pp. 743-766.
375. Thase, M.E., Haight, B.R., Richard, N. et al. (2005) Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. Journal of Clinical Psychiatry, 66, 974-981.
376. Thase, M.E., Friedman, E.S., Biggs, M.M. et al. (2007) Cognitive therapy versus medication in augmentation and switch strategies as secondstep treatments: A STAR*D report. American Journal of Psychiatry, 164, 739-752.
377. The ALLHAT CollaborativeResearch Group (2002) Major outcomes in highrisk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA, 288, 2981-2997.
378. The TADS Team (2007) The Treatment for Adolescents With Depression Study (TADS): Long-term effectiveness and safety outcomes. Archives of General Psychiatry, 64, 1132-1144.
379. Thieda, P., Beard, S., and Richter, A. (2003) An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatric Services, 54, 508-516.
380. Thombs, B.D., de Jonge, P., Coyne, J.C., and Whooley, M.A. (2008) Depression screening and patient outcomes in cardiovascular care: A systematic review. JAMA, 300, 2161-2171.
381. Thompson, A., Sullivan, S.A., Barley, M. et al. (2008) The DEBIT trial: an intervention to reduce antipsychotic polypharmacy prescribing in adult psychiatry wards - a cluster randomized controlled trial. Psychological Medicine, 38, 705-715.
382. Tiihonen, J., Lonnqvist, J., Wahlbeck, K. et al. (2009) 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet, 364, 620-627.
383. Tohen, M., Chengappa, K.N.R., Suppes, T. et al. (2006) Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabilizer vs. mood stabilizer alone. British Journal of Psychiatry, 184, 337-345.
384. Tondo, L., Baldessarini, R., and Floris, G. (2001) Long-term clinical effectiveness of lithium maintenance treatment in types I and II bipolar disorders. British Journal of Psychiatry, 178, s184-s190.
385. Tone, A. (2008) The Age of Anxiety, Basic Books, New York.
386. Torrens, M., Fonseca, F., Mateu, G., and Farre, M. (2005) Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis. Drug & Alcohol Dependence, 78, 1-22.
387. Tost, H., Alam, T., and Meyer-Lindenberg, A. (2009) Dopamine and psychosis: theory, pathomechanisms and intermediate phenotypes. Neuroscience and Behavioral Reviews (published on line, June).
388. Trivedi, M.H., Rush, A.J.,Wisniewski, S.R. et al. (2006a) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR D: implications for clinical practice. American Journal of Psychiatry, 163, 28-40.
389. Trivedi, M.H., Fava, M., Wisniewski, S.R. et al. (2006b) Medication augmentation after the failure of SSRIs for depression. New England Journal of Medicine, 354, 1243-1252.
390. Tsapakis, E.M., Soldani, L., and Baldessarini, R. (2008) Efficacy of antidepressants in juvenile depression: meta-analysis. British Journal of Psychiatry, 193, 10-17.
391. Turkington, D., Kingdon, D., and Weiden, P.J. (2006) Cognitive behavior therapy for schizophrenia. American Journal of Psychiatry, 163, 365-373.
392. Turner, E.H., Matthews, A.M., Linardatos, E. et al. (2008) Selective publication of antidepressant trials. NEJM, 358, 2180-2182.
393. Twenge, J.M., and Campbell,W.K. (2009) The Narcissism Epidemic: Living in the Age of Entitlement, Simon and Schuster, New York.
394. Tyrer, P., and Kendall, T. (2009) The spurious advance of antipsychotic drug therapy. Lancet, 361, 1591-1592.
395. Valenstein, E.S. (1986) Great and Desperate Cures, Basic, New York.
396. Valenstein, E.S. (1998) Blaming the Brain: The Real Truth About Drugs and Mental Health, Free Press, New York.
397. Valenstein, M. (2006) Keeping Our Eyes on STAR*D. American Journal of Psychiatry, 193, 1484-1486.
398. Valenstein, E.S. (2005) War of the Soups and the Sparks: The Discovery of Neurotransmitters and the Dispute over How Nerves Communicate, Columbia University Press, New York.
399. van Vliet, I.M., den Boer, J.A., and Westenberg, H.W. (1994) Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology, 115, 128-134.
400. Viguera, A.D., Baldessarini, R.J., and Friedberg, J. (1999) Discontinuing antidepressant treatment in major depression. Harvard Reviewof Psychiatry, 5, 293-306.
401. Wakefield, J.C., Horwitz, A.V., and Schmitz, M.F. (2004) Are we overpathologizing the socially anxious? social phobia from a harmful dysfunction perspective. Canadian Journal of Psychiatry, 49, 736-742.
402. Wakefield, J.C., Schmitz, M.F., First, M.B., and Horwitz, A. (2007) Extending the bereavement exclusion for major depression to other losses. Archives of General Psychiatry, 64, 43-440.
403. Walsh, B.T., Seidman, S.N., Sysko, R., and Gould, M. (2002) Placebo response in studies of major depression: variable, substantial, and growing. JAMA, 287, 1840-1847.
404. Wampold, B.E. (2001) The Great Psychotherapy Debate: Models, Methods, and Findings, Erlbaum Associates, Mahwah, N.J.
405. Watanabe, N., Omori, I.M., Nagagawa, A. et al. (2008) Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review andmeta-analysis. Journal of Clinical Psychiatry, 69, 1404-1415.
406. Wazana, A. (2000) Physicians and the Pharmaceutical Industry: Is a gift ever just a gift? JAMA, 283, 373-380.
407. Weisler, R., Joyce, M., McGill, L. et al. (2009) Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectrums, 14, 299-313.
408. Weiss, G., and Hechtman, L. (1993) Hyperactive ChildrenGrown Up: ADHD in Children, Adolescents, and Adults, 2nd edn, Guilford, New York.
409. Weissman, M.M. (2007) Recent non-medication trials of interpersonal psychotherapy for depression. The International Journal of Neuropsychopharmacology, 10, 117-122.
410. Westen, D., and Morrison, K. (2001) A multidimensional meta-analysis of treatments for depression, panic, and generalized anxiety disorder: an empirical examination of the status of empirically supported therapies. Journal of Consulting & Clinical Psychology, 69, 875-899.
411. Whitehead, C., Moss, S., Cardno, A., and Lewis, G. (2003) Antidepressants for the treatment of depression in people with schizophrenia: a systematic review. Psychological Medicine, 33, 589-599. Review: the case for antidepressants for treating depression in people with schizophrenia remains unproven.
412. Wijkstra, J., Lijmer, J., Balk, F.J., Geddes, J.R., Nolen,W.A. (2006) Pharmacological treatment for unipolar psychotic depression: Systematic review and meta-analysis. British Journal of Psychiatry, 188, 410-5.
413. Williamson, P. (2006) Mind, Brain, and Schizophrenia, Oxford University Press, New York.
414. Woerner, M.G., Alvir, J.M.J., Saltz, B.L., Lieberman, J.A., and Kane, J.M. (1998) Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry 155, 1521-1528.
415. Woods, J.H., Katz, J.L., and Winger, G. (1988) Use and abuse of benzodiazepines. Issues relevant to prescribing. JAMA, 260, 3476-3480.
416. World Health Organization (1992) International Classification of Diseases, 10th edn, WHO, Geneva.
417. Wozniak, J. (2005) Recognizing and managing bipolar disorder in children. Journal of Clinical Psychiatry, 66 (Suppl 1), 18-23.
418. Young, A. (1997) The Harmony of Illusions: Inventing Post-Traumatic Stress Disorder, Princeton University Press, Princeton, NJ.
419. Young, S., and Annable, L. (2002) The ethics of placebo in clinical psychopharmacology: the urgent need for consistent regulation. Journal of Psychiatry & Neuroscience, 27, 319-321.
420. Young, T. (2008) What is the best treatment for bipolar depression? J Psychiatry Neuroscience, 33, 487-488.
421. Zanarini, M.C., Frankenburg, F.R., Khera, G.S., and Bleichmar, J. (2001) Treatment histories of borderline inpatients. Comprehensive Psychiatry, 42, 144-150.
422. Zhou, L., Huang, K., Kecojevic, A. et al. (2006) Evidence that serotonin reuptake modulators increase the density of serotonin innervation in the forebrain. Journal of Neurochemistry, 96, 396-406.
423. Zimmerman, M., Ruggero,C.J., Chelminski, I., andYoung, D. (2008) Is bipolar disorder overdiagnosed? Journal of Clinical Psychiatry, 69, 935-940.
424. Zoccolillo, M., Pickles, A., Quinton, D., and Rutter, M. (1992) The outcome of childhood conduct disorder: implications for defining adult personality disorder and conduct disorder. Psychological Medicine, 22, 971-986.